정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 821 | Recruiting | Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome | Cytokine Storm | Drug: BAT + Calcifediol Drug: BAT |
Phase 2 | Maimonides Biomedical Research Institute of Cordoba, Junta de Andalucia - Consejeria de Salud y Familias, Spain, Dynamic Solutions, Faes Farma, S.A. | OTHER | 1008 | All | 18 Years ~ 90 Years | Hospital Universitario Reina Sofia, Cordoba, Spain |
| 820 | Recruiting | Prevention and Treatment With Hydroxychloroquine + Azithromycin of Acute Respiratory Syndrome Induced by COVID-19 | Covid19 | Drug: Hydroxychloroquine Pill + Azithromycin Pill Drug: SOC |
Phase 2 | Maimonides Biomedical Research Institute of Cordoba | OTHER | 132 | All | 18 Years ~ 90 Years | Centro de Salud Priego de Cordoba, Priego de Cordoba, Cordoba, Spain |
| 819 | Recruiting | Prevention of Acute Myocardial Injury by Trimetazidine in Patients Hospitalized for COVID-19 | Myocardial Injury | Drug: Trimetazidine | Phase 2 | Ministry of Health, Brazil, InCor Heart Institute | OTHER_GOV | 80 | All | 18 Years | Heart Institute (InCor-HCFMUSP), Sao Paulo, SP, Brazil |
| 818 | Recruiting | Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial | Arterial Thrombosis | Drug: Unfractionated Heparin IV Drug: Enoxaparin 1 mg/kg Drug: Clopidogrel Drug: Unfractionated heparin SC Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution |
Phase 4 | The TIMI Study Group | OTHER | 750 | All | 18 Years | Brigham and Women's Hospital, Boston, Massachusetts, United States |
| 817 | Completed | Prevention of Complications (SARS-CoV-2): Clinical Study | Complication | Drug: Control group (standard hospital treatment) Drug: Group Hydroxychloroquine Drug: Group Hydroxychloroquine and apixaban Drug: Group Apixaban |
Phase 3 | Universidade do Vale do Sapucai, Pfizer, Apsen Farmaceutica S.A., Dermadia, Methodos Laboratory, Biofarma | OTHER | 176 | All | 18 Years | Univas, Pouso Alegre, Minas Gerais, Brazil |
| 816 | Completed | Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide | Coronavirus Infection | Drug: Nitazoxanide 500Mg Oral Tablet | Phase 4 | Materno-Perinatal Hospital of the State of Mexico, Laboratorios Liomont | OTHER | 150 | All | 18 Years ~ 80 Years | Materno-Perinatal Hospital "Monica Pretelini", Toluca, Mexico |
| 815 | Not yet recruiting | Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) | Hydroxychloroquine | Drug: Hydroxychloroquine Only Product in Oral Dose Form | Phase 3 | University of Malaga, Instituto de Investigacion Biomedica de Malaga, Carlos III Health Institute | OTHER | 1930 | All | 18 Years |